LONDON (Alliance News) - Life sciences company ValiRx PLC on Tuesday said it has signed a three-year collaboration deal with Finnish contract research organisation Pharmatest to develop further products and compounds from ValiRx's gene activation technology platform.
ValiRx's GeneICE technology allows the selective silencing of "rebellious" or inappropriately active genes which can contribute to a number of diseases, including cancer.
No financial details on the agreement were revealed.
"ValiRx is happy to enter into this three-year agreement with Pharmatest. The work that Pharmatest has done for ValiRx in our other programmes during the past years has been of very high quality, and we are convinced that this agreement will substantially speed up the development of future GeneICE projects," said Satu Vainikka, ValiRx's chief executive.
Shares in ValiRx were down 2.7% to 25.30 pence on Tuesday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
ValiRx (VAL)